CL2016000300A1 - Métodos terapéuticos - Google Patents

Métodos terapéuticos

Info

Publication number
CL2016000300A1
CL2016000300A1 CL2016000300A CL2016000300A CL2016000300A1 CL 2016000300 A1 CL2016000300 A1 CL 2016000300A1 CL 2016000300 A CL2016000300 A CL 2016000300A CL 2016000300 A CL2016000300 A CL 2016000300A CL 2016000300 A1 CL2016000300 A1 CL 2016000300A1
Authority
CL
Chile
Prior art keywords
therapeutic methods
therapeutic agent
compound
hepatitits
hcv
Prior art date
Application number
CL2016000300A
Other languages
English (en)
Inventor
Jill Walker
Christian Voitenleitner
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CL2016000300A1 publication Critical patent/CL2016000300A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE UN COMPUESTO 2-FENIL-BENZOFURANO SUSTITUIDO Y UN SEGUNDO AGENTE TERAPEUTICO, PARA EL TRATAMIENTO DEL VIRUS DE LA HEPATITITS C (HCV); Y COMPOSICION QUE COMPRENDE A DICHO COMPUESTO Y AL SEGUNDO AGENTE TERAPEUTICO.
CL2016000300A 2011-08-17 2016-02-05 Métodos terapéuticos CL2016000300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161524429P 2011-08-17 2011-08-17
US201161526787P 2011-08-24 2011-08-24

Publications (1)

Publication Number Publication Date
CL2016000300A1 true CL2016000300A1 (es) 2016-09-02

Family

ID=47715500

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2014000394A CL2014000394A1 (es) 2011-08-17 2014-02-17 Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.
CL2016000300A CL2016000300A1 (es) 2011-08-17 2016-02-05 Métodos terapéuticos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2014000394A CL2014000394A1 (es) 2011-08-17 2014-02-17 Uso de compuestos fenil-benzofuran-sulfamido sustituidos para el tratamiento del virus de la hepatitis c (hcv); y composicion farmaceutica que comprende a estos compuestos fenil-benzofuran-sulfamido sustituidos.

Country Status (21)

Country Link
US (2) US9119868B2 (es)
EP (1) EP2744342B1 (es)
JP (2) JP6121419B2 (es)
KR (2) KR20140093209A (es)
CN (2) CN106109479A (es)
AU (1) AU2012296446B2 (es)
BR (1) BR112014003556A2 (es)
CA (1) CA2843502C (es)
CL (2) CL2014000394A1 (es)
CO (1) CO6880064A2 (es)
CR (1) CR20140075A (es)
DO (1) DOP2014000030A (es)
EA (2) EA201690327A1 (es)
ES (1) ES2735542T3 (es)
IL (1) IL230484A (es)
MA (1) MA35347B1 (es)
MX (1) MX2014001833A (es)
PE (1) PE20141391A1 (es)
SG (1) SG10201606646RA (es)
WO (1) WO2013025992A1 (es)
ZA (2) ZA201400435B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013025992A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Therapeutic methods
MX354676B (es) * 2011-08-19 2018-03-15 Glaxo Group Ltd Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
KR20170081257A (ko) * 2014-11-10 2017-07-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 C형 간염에 대한 조합 장기 작용 조성물 및 방법
PE20170921A1 (es) * 2014-11-10 2017-07-12 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas de accion prolongada para la hepatitis c
CN105732602B (zh) * 2015-09-23 2017-04-19 常州寅盛药业有限公司 作为ns4b抑制剂的苯并呋喃类似物
CN110799193B (zh) * 2017-03-21 2023-12-12 斯克利普斯研究院 铜和镍催化的脱羧硼化反应
KR20220088736A (ko) * 2019-10-25 2022-06-28 스미토모 파마 가부시키가이샤 신규 치환 축환형 화합물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5920400A (en) * 1999-07-07 2001-01-22 Du Pont Pharmaceuticals Company Cell-based assay systems for examining hcv ns3 protease activity
US7265152B2 (en) * 2002-11-01 2007-09-04 Viropharma Incorporated Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
WO2005051318A2 (en) 2003-11-24 2005-06-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
CA2651212A1 (en) * 2006-05-02 2007-11-15 Anacor Pharmaceuticals, Inc. Hydrolytically-resistant boron-containing therapeutics and methods of use
MX2010001650A (es) 2007-08-10 2010-08-02 Glaxosmithkline Llc Entidades quimicas biciclicas que contienen nitrogeno para el tratamiento de infecciones virales.
GB0719366D0 (en) * 2007-10-03 2007-11-14 Smithkline Beecham Corp Compounds
ES2377280T3 (es) * 2008-02-14 2012-03-26 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2011050284A1 (en) * 2009-10-23 2011-04-28 Glaxosmithkline Llc Pyrazolylpyridine antiviral agents
WO2011103063A1 (en) 2010-02-19 2011-08-25 Glaxo Group Limited Therapeutic compounds
WO2012067663A1 (en) 2010-11-18 2012-05-24 Glaxo Group Limited Compounds
WO2013025975A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Combination treatments for hepatitis c
WO2013025992A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc Therapeutic methods
MX354676B (es) * 2011-08-19 2018-03-15 Glaxo Group Ltd Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
CA2845321A1 (en) * 2011-08-24 2013-02-28 Glaxosmithkline Llc Combination treatments for hepatitis c

Also Published As

Publication number Publication date
AU2012296446B2 (en) 2015-07-09
CR20140075A (es) 2014-03-24
JP6121419B2 (ja) 2017-04-26
EA024357B1 (ru) 2016-09-30
KR20180129973A (ko) 2018-12-05
US9119868B2 (en) 2015-09-01
ZA201502595B (en) 2017-01-25
ES2735542T3 (es) 2019-12-19
EA201490199A1 (ru) 2015-01-30
CN106109479A (zh) 2016-11-16
EA201490199A8 (ru) 2015-12-30
CA2843502A1 (en) 2013-02-21
US10238678B2 (en) 2019-03-26
KR20140093209A (ko) 2014-07-25
IL230484A0 (en) 2014-03-31
CN103929965B (zh) 2016-08-17
US20150320777A1 (en) 2015-11-12
MX2014001833A (es) 2014-02-27
JP2014524446A (ja) 2014-09-22
PE20141391A1 (es) 2014-10-29
CA2843502C (en) 2019-01-15
WO2013025992A1 (en) 2013-02-21
EP2744342A1 (en) 2014-06-25
CO6880064A2 (es) 2014-02-28
MA35347B1 (fr) 2014-08-01
US20140212384A1 (en) 2014-07-31
AU2012296446A1 (en) 2014-02-13
CL2014000394A1 (es) 2014-08-01
EP2744342B1 (en) 2019-04-24
EA201690327A1 (ru) 2016-06-30
KR101975233B1 (ko) 2019-05-07
EP2744342A4 (en) 2015-01-28
IL230484A (en) 2016-11-30
BR112014003556A2 (pt) 2017-03-21
JP2017165732A (ja) 2017-09-21
ZA201400435B (en) 2015-09-30
SG10201606646RA (en) 2016-09-29
NZ619985A (en) 2016-06-24
CN103929965A (zh) 2014-07-16
DOP2014000030A (es) 2014-06-30

Similar Documents

Publication Publication Date Title
CL2014003634A1 (es) Inhibidores del virus de la hepatitis c
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2016000300A1 (es) Métodos terapéuticos
CL2016000381A1 (es) Compuestos antivirales
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CL2017001798A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas.
CL2013001428A1 (es) Compuesto que inhibe la actividad del virus de la hepatitis c (hcv); composición farmacéutica que comprende el compuesto; método de tratamiento de hepatitis c.
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CO6761348A2 (es) Compuestos antivirales
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
CL2015000942A1 (es) Compuestos de benceno sustituido.
CL2013001141A1 (es) Compuestos derivados de heterociclos condensados, inhibidores del virus de la hepatitis c; composicion farmaceutica que los contiene; y su uso para el tratamiento de la infeccion por el virus de la hepatitis c.
CL2015000870A1 (es) Análogos de 2' -cloro nucleósido para infección por vhc.
CL2012002057A1 (es) Compuestos macrociclicos sustituidos, como inhibidores del virus de la hepatitis c; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende, utiles como agente antivirales.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
ECSP14013315A (es) Inhibidores de aplicación viral
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
CO6761335A2 (es) Inhibidores del virus de la hepatitis c
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
CL2015001971A1 (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas.
CL2010001634A1 (es) Compuestos derivados de nucleosidos, inhibidores del virus de la hepatitis c; procedimiento de preparacion; composicion farmaceutica que los comprende; y combinacion farmaceutica.
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas